Episurf Medical provides update on establishment of US commercial organisation
Episurf Medical (Nasdaq: EPIS B) today provides an update on the establishment of a US commercial organisation. In line with its strategy for the US market and its first product on the US market, the Episealer® Patellofemoral System, Episurf Medical is building a network of third-party distributors. The company has recently signed agreements with numerous third-party distributors servicing a cumulative population base of nearly 50 million people, with several more agreements expected to be signed in the coming weeks and months. Initially targeted distributors include those already doing other business with high volume surgeons and that previously were leading revenue performers of competitive products. The group already under agreement collectively distributes for nearly every major orthopaedic manufacturer in the industry without a conflicting offering.
“To date, the response to Episurf’s Patellofemoral System from both surgeons and distributors has been overwhelmingly positive. Surgeons willingly acknowledge the space within the market where Episurf seeks to fill, as well as the shortcomings of currently available offerings. Paired with the successful clinical history of the Episealer® Knee system in Europe, it is clear that our portfolio, present and future, is and will be seen as a welcomed addition to the orthopaedic community in the US After initial surgeon interest is garnered, every hospital system in the country has their own new vendor approval process to work through, and we have begun this work with numerous facilities from coast to coast”, said Patrick Jamnik, President, Episurf Medical, Inc.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 11 April 2023.
Tags: